Phase II
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
Shares of Kaleido Biosciences are plunging after the company announced its intentions to cease all company operations, lay off its remaining staff and delist from the Nasdaq Exchange.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
Janssen’s Phase II study of nipocalimab for generalized myasthenia gravis (gMG) shows that serum IgG levels can be used as a supportive biomarker to manage this disease.
Aptinyx therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy failed to produce significant results. Here is why it happened.
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
This morning, Merck hosted a cardiovascular investment event where it touted the advances it’s made in its pipeline, which includes a portfolio that has tripled in size over the past year.
Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
PRESS RELEASES